1-3 of 3
Matthew C. Canver, MD PhD
Close
Sort by
Journal Articles

Paics, a De Novo Purine Synthetic Enzyme, Is a Novel Target for AML Therapy

Takuji Yamauchi, MD PhD, Kohta Miyawaki, MD, Yuichiro Semba, MD PhD, Fumihiko Nakao, MD, Takeshi Sugio, MD PhD, Kensuke Sasaki, MD, Jumpei Nogami, PhD, Matthew C. Canver, MD PhD, Simon Osborne, PhD, Luca Pinello, PhD, Deborah Taylor, PhD, Daniel E. Bauer, MD PhD, Koichi Akashi, MD PhD, Takahiro Maeda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1390.
https://doi.org/10.1182/blood-2019-127047
Published: 2019
Journal Articles

CRISPR-Cas9 Screen Identifies XPO7 As a Potential Therapeutic Target for TP53 -Mutated AML

Yuichiro Semba, MD PhD, Takuji Yamauchi, MD PhD, Fumihiko Nakao, MD, Jumpei Nogami, PhD, Matthew C. Canver, MD PhD, Luca Pinello, PhD, Daniel E. Bauer, MD PhD, Koichi Akashi, MD PhD, Takahiro Maeda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3784.
https://doi.org/10.1182/blood-2019-129623
Published: 2019
Journal Articles

Rational Targeting of a NuRD Sub-Complex for Fetal Hemoglobin Induction Following Comprehensive in Situ Mutagenesis

Mir Hossain, PhD, Falak Sher, PhD, Davide Seruggia, PhD, Vivien Schoonenberg, BS, Mitchel A. Cole, BS, Paolo Cifani, PhD, Laura Dassama, PhD, Claudio Macias-Trevino, BS, Matthew C. Canver, MD PhD, Ryo Kurita, PhD, Yukio Nakamura, MD PhD, Luca Pinello, PhD, Takahiro Maeda, MD PhD, Alex Kentsis, MD PhD, Stuart H. Orkin, MD, Daniel E. Bauer, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2342.
https://doi.org/10.1182/blood-2018-99-117043
Published: 2018